Почетна › Steatotna bolest jetre › Северна Каролина
Kliničke studije za Steatotna bolest jetre u državi Северна Каролина
14 studija za Steatotna bolest jetre traži učesnike na lokacijama u državi Северна Каролина.
Gradovi u državi Северна Каролина
Zvanični tekst studije (na engleskom)
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Chapel Hill
Тражи се учесникФаза 2
Узраст од 18 до 70 · Оба пола · Ажурирано 13. 11. 2026. · NCT06613698A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chapel Hill
- Akero Clinical Study Site, Charlotte
- Akero Clinical Study Site, Charlotte
- и још 5
Тражи се учесникФаза 3
Узраст од 18 до 80 · Оба пола · Ажурирано 12. 11. 2026. · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Coastal Research Institute, Fayetteville
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 9. 11. 2026. · NCT07288138A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Wilson
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 5. 11. 2026. · NCT06920043A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Morehead City
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 5. 11. 2026. · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Morehead City
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 5. 11. 2026. · NCT07701993A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Asheville
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- и још 2
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 23. 10. 2026. · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- 89bio Clinical Study Site, Fayetteville
- и још 3
Тражи се учесникФаза 3
Узраст од 18 до 80 · Оба пола · Ажурирано 23. 10. 2026. · NCT06318169A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Duke University - Main Hospital and Clinics, Durham
- Monroe Biomedical Research, Monroe
- Carteret Medical Group, Morehead City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07165028Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Duke Liver Center, Durham
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 28. 9. 2026. · NCT05832229A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Morehead City
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 17. 9. 2026. · NCT07221188A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Morehead City
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 27. 7. 2026. · NCT07221227Androgens and NAFLD Longitudinal Cohort Study
- Duke University, Durham
Тражи се учесникОпсервациона студија
Узраст од 18 до 42 · Жене · Ажурирано 13. 4. 2026. · NCT06124261Siemens Biomarker Multi-modality
- Duke University Medical Center, Durham
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 3. 4. 2026. · NCT07495332Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.